Drug combination for advanced neuroendocrine carcinoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called neuroendocrine carcinoma that has spread or cannot be removed by surgery (but not small cell lung cancer).
- Your cancer has gotten worse or you had bad side effects after at least one previous treatment.
- You have at least one tumor that can be measured on a scan.
- You are between 18 and 75 years old and your overall health is good enough to be up and about (ECOG score 0-1).
- You have not had prior treatment with immunotherapy (like Keytruda or Opdivo), anti-VEGF drugs (like Avastin), or the chemotherapy temozolomide.
- Your blood counts, liver, kidney, and other organ functions are within acceptable ranges (tests done within 7 days before starting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) in people whose advanced neuroendocrine carcinoma has stopped responding to standard first-line treatment. The goal is to see if this special formulation can help slow or shrink the cancer.
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
This trial tests a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) added to a standard chemotherapy regimen called FOLFIRI, to see if it works better than FOLFIRI alone for a rare and aggressive type of cancer called neuroendocrine carcinoma. It is for people whose cancer has progressed after a first-line chemotherapy, and aims to help slow the cancer's growth.
This trial tests a combination of two oral and intravenous drugs – surufatinib and tislelizumab – for people with advanced lung cancer that shows certain hormone-like cell traits. The goal is to see if this pair can shrink or slow the cancer better than current treatments.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.